Verve Therapeutics Inc. (NASDAQ:VERV)’s traded shares stood at 2.04 million during the last session. At the close of trading, the stock’s price was $16.48, to imply a decrease of -2.60% or -$0.44 in intraday trading. The VERV share’s 52-week high remains $43.00, putting it -160.92% down since that peak but still an impressive 35.07% since price per share fell to its 52-week low of $10.70. The company has a valuation of $1.04B, with an average of 0.95 million shares in intraday trading volume over the past 10 days and average of 697.65K shares over the past 3 months.
Analysts have given a consensus recommendation of an Overweight for Verve Therapeutics Inc. (VERV), translating to a mean rating of 2.10. Of 11 analyst(s) looking at the stock, 1 analyst(s) give VERV a Sell rating. 0 of those analysts rate the stock as Overweight while 3 advise Hold as 7 recommend it as a Buy. 0 analyst(s) have given it an Underweight rating. Estimates put the company’s current-quarter earnings per share at -$0.76.
Do You Know The Best Place To Find Gains In Volatile Markets?
In today's chaotic marketplace, the biggest gains will come from some currently-small companies that pass by older, larger businesses still stuck in a pre-pandemic world. The trick is figuring out which small caps will be tomorrow's winners. That's why StockWire News has put together a special Wealth Building Report, highlighting 3 small cap stocks set to soar in 2023.
Click here for full details and to join for free.
Verve Therapeutics Inc. (NASDAQ:VERV) trade information
After registering a -2.60% downside in the last session, Verve Therapeutics Inc. (VERV) has traded red over the past five days. The stock hit a weekly high of 18.66 this Friday, 03/17/23, dropping -2.60% in its intraday price action. The 5-day price performance for the stock is -3.51%, and -24.13% over 30 days. With these gigs, the year-to-date price performance is -14.83%. Short interest in Verve Therapeutics Inc. (NASDAQ:VERV) saw shorts transact 12.79 million shares and set a 14.86 days time to cover.
Analysts on Wall Street suggest a consensus price target of $42.60, implying an increase of 61.31% to the stock’s current value. The extremes give us $14.00 and $75.00 for target low and target high price respectively. As such, VERV has been trading -355.1% off suggested target high and 15.05% from its likely low.
Verve Therapeutics Inc. (VERV) estimates and forecasts
Looking at statistics comparing Verve Therapeutics Inc. share performance against respective industry, we note that the company has underperformed competitors. Verve Therapeutics Inc. (VERV) shares are -60.28% down over the last 6 months, with its year-to-date growth rate lower than industry average at -7.90% against 10.80%. Revenue is forecast to shrink -16.90% this quarter before falling -24.20% for the next one.
Verve Therapeutics Inc. has its next earnings report out in April. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too. Verve Therapeutics Inc. has a forward dividend ratio of 0, with the share yield ticking at 0.00% to continue the rising pattern observed over the past year. The company’s average dividend yield trailing the past 5-year period is 0.00%.
Verve Therapeutics Inc. (NASDAQ:VERV)’s Major holders
Verve Therapeutics Inc. insiders hold 9.94% of total outstanding shares, with institutional holders owning 106.17% of the shares at 117.88% float percentage. In total, 106.17% institutions holds shares in the company, led by Alphabet Inc. As of Sep 29, 2022, the company held over 10.97 million shares (or 17.81% of shares), all amounting to roughly $376.96 million.
The next major institution holding the largest number of shares is FMR, LLC with 7.48 million shares, or about 12.15% of shares outstanding. As of the market price on Sep 29, 2022, these shares were worth $257.02 million.
We also have SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF and ARK ETF Tr-ARK Genomic Revolution ETF as the top two Mutual Funds with the largest holdings of the Verve Therapeutics Inc. (VERV) shares. Going by data provided on Dec 30, 2022, SPDR (R) Ser Tr-SPDR (R) S&P (R) Biotech ETF holds roughly 3.57 million shares. This is just over 5.79% of the total shares, with a market valuation of $69.01 million. Data from the same date shows that the other fund manager holds a little less at 2.67 million, or 4.33% of the shares, all valued at about 51.6 million.